The aim of this study is control and treatment of chronic hypertension in pregnancy. Also, improve outcomes of fetal and maternal. 80 pregnant women with chronic hypertension for prenatal care that referring to Al-Zahra hospital from the date of approval of plan to complete the sample collection will be included and in the absence of consent to participate will be excluded from study. Blood pressure is measured at each visit with adult standard sphygmomanometer. Blood pressure tried to be preserved between 90/140 to 100/150. If blood pressure is higher than 109/159, anti-hypertensive therapy with methyldopa 250 mg every 12 hours is starting and 3 days later will visit again. If blood pressure is higher than 100/150, we add a dose and if we got to 4 tablets per day and at weekly intervals of control of blood pressure10 mg Hydralazine tablets will added every 12 hours and if necessary increase the dose. If treatments in next controls are not effective, we will use Nifedipine. Dosage adjustment is in order to maintain blood pressure between 100-90/150. In the meantime, at every visit, maternal and perinatal outcomes will be monitored.
Maternal outcomes included:HELLP Syndrome, stroke, acute kidney injury, heart failure, placental abruption and maternal mortality.
Prenatal outcomes included: fetal death, growth restriction, preterm delivery, fetal death, neonatal morbidity.
In case of bad consequences, the mother is hospitalized and further evaluation and treatment measures are done. For each patient, type of prescribed medication, dose, the number of divided doses, time and bad consequences of maternal and perinatal will be recorded. Based on the research question, Patients in need with Anti-hypertensive medicine less than 5 divided doses or 5 or more than 5 is divided into two groups. Undesirable outcomes of maternal and perinatal among two groups are compared. This study is not blinded.